Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 3 2

Status

Recruiting 3Terminated 1Completed 1Available 1Active not recruiting 1

Sponsor Class

INDUSTRY 7OTHER 5

Study Type

Interventional 6Expanded_access 1

Sponsor

Cancer Type

Dermatologic 6Thoracic 1Head & Neck 1Gynecologic 1

Conditions

Melanoma 5Skin Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Melanoma, Cutaneous Malignant 1Endometrial Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 1029Carboplatin 966Paclitaxel 941Gemcitabine 798Cisplatin 754Docetaxel 697Bevacizumab 638Nivolumab 519Pemetrexed 507Capecitabine 475Cyclophosphamide 468Fluorouracil 424Dexamethasone 409Rituximab 391Oxaliplatin 351Injections 344Trastuzumab 313atezolizumab 311Cetuximab 291Leucovorin 288Irinotecan 269130-nm albumin-bound paclitaxel 255Prednisone 250Ipilimumab 244Doxorubicin 241Lenalidomide 231Fulvestrant 226fludarabine 215durvalumab 211Erlotinib Hydrochloride 196

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
INDUSTRY × lifileucel × Clear all
NCT03645928 2026-05-15

Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors

Iovance Biotherapeutics, Inc.

Phase 2 Terminated
225 enrolled
DermatologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma

NCT06743126 2026-04-21

SUPRAME

Immatics US, Inc.

Phase 3 Recruiting
360 enrolled
Dermatologic

Melanoma, Cutaneous Malignant

NCT05398640 2026-04-20

Expanded Access Program of AMTAGVI That is Out of Specification for Commercial Release

Iovance Biotherapeutics, Inc.

Available
Dermatologic

Melanoma

NCT07288203 2026-04-20

A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma

Iovance Biotherapeutics, Inc.

Phase 2 Active not recruiting
100 enrolled
Dermatologic

Melanoma, Skin Neoplasms

NCT05727904 2026-04-03

Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.

Iovance Biotherapeutics, Inc.

Phase 3 Recruiting
670 enrolled
Dermatologic

Melanoma, Skin Neoplasms

NCT02360579 2026-03-25

LN-144

Iovance Biotherapeutics, Inc.

Phase 2 Completed
220 enrolled 16 charts
Dermatologic

Melanoma

NCT06481592 2025-10-30

A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.

Iovance Biotherapeutics, Inc.

Phase 2 Recruiting
60 enrolled
Gynecologic

Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡